← Back to Search

mTOR Inhibitor

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by Calithera Biosciences, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new medication aimed at treating a specific type of lung cancer. It targets patients whose cancer has not responded to at least two previous treatments. The drug works by stopping the growth of cancer cells.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Lung Cancer
  • NFE2L2 Gene Mutation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Investigator-Assessed Overall Response Rate (ORR) per RECIST v1.1.
Number of Participants With Adverse Events (AEs), Serious AEs, Deaths, and Discontinuations Due to AEs
Secondary study objectives
Duration of Response (DOR)
Overall Survival (OS)
Overall Survival (OS) at 12 Months
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Group B - NFE2L2 Wild-Type, Dosing Cohort 2Experimental Treatment1 Intervention
sapanisertib 2 mg BID
Group II: Group B - NFE2L2 Wild-Type, Dosing Cohort 1Experimental Treatment1 Intervention
sapanisertib 3 mg QD
Group III: Group A - NFE2L2 Mutation, Dosing Cohort 2Experimental Treatment1 Intervention
sapanisertib 2 mg twice daily (BID)
Group IV: Group A - NFE2L2 Mutation, Dosing Cohort 1Experimental Treatment1 Intervention
sapanisertib 3 mg once daily (QD)

Find a Location

Who is running the clinical trial?

Calithera Biosciences, IncLead Sponsor
33 Previous Clinical Trials
2,014 Total Patients Enrolled
Bradley J Sumrow, MDStudy DirectorCalithera Biosciences, Inc
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top